Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal…Read More
You might also be interested in reading Lumerin and Quai Announce Strategic Collaboration to Enable On-Chain Compute Power Trading.